Evotec Biologics Introduces J.TRAIN for 500 kg-Scale Continuous Manufacturing in 18 Months
EVO•Evotec SE’s Just – Evotec Biologics has launched J.TRAIN, a turnkey continuous manufacturing platform combining modular cleanrooms and cGMP process automation for partner-owned facilities. J.TRAIN can produce over 500 kg of drug substance in under 10 000 sq ft, delivers tenfold higher productivity than fed-batch methods with 18-month deployment timelines.
1. Launch of J.TRAIN Platform
Evotec's Just – Evotec Biologics division has introduced J.TRAIN, a turnkey solution combining prefabricated modular cleanrooms, industry-standard equipment and proprietary cGMP automation scripts to establish continuous biologics manufacturing capabilities onsite at partner-owned facilities.
2. Technical Capabilities and Productivity Gains
J.TRAIN can produce more than 500 kilograms of biologic drug substance within less than 10,000 square feet, delivering over ten times the productivity of conventional fed-batch processes. Integrated automation and digital validation protocols support rapid product changeovers and flexible scale adjustments during manufacturing runs.
3. Deployment Timeline and Cost Efficiency
Modular infrastructure allows for facility deployment in approximately 18 months, substantially faster than traditional builds. This capital-light model reduces operating costs per unit mass and streamlines implementation with digital training and documentation protocols.
4. Strategic Implications for Evotec
By licensing technology and providing process design and engineering, Evotec positions J.TRAIN as a disruptive service offering to attract biopharma partners seeking fast capacity expansion. Validation from a December 2025 Sandoz transaction underscores the feasibility and scalability of this business model.
